Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NACDS pharmacy affairs

Executive Summary

National Association of Chain Drug Stores reinstates its pharmacy affairs department. The new department, led by Senior VP Edith Rosato, will include three areas: pharmacy practice & operations; education, research & grants; and external relations & the NACDS foundation. The association had merged its pharmacy operations department with pharmacy regulatory & policy affairs in 2005 following the departure of Senior VP-Pharmacy Operations Kurt Proctor (1"The Pink Sheet" Aug. 8, 2005, In Brief)....

You may also be interested in...



NACDS reorganization

The National Association of Chain Drug Stores undergoes a reorganization following the departure of Senior VP-Pharmacy Operations Kurt Proctor. Proctor, who had been with NACDS for 16 years, left the trade group to pursue other opportunities, NACDS said Aug. 4. The pharmacy operations department is being merged with pharmacy regulatory & policy affairs, and the realigned department will be headed by Mary Ann Wagner, who is being promoted to senior VP-pharmacy, policy & regulatory affairs. COO Bill Sittman, who is adding the title of exec VP, will oversee the new department. CFO Jim Huber is also named exec VP. The changes took effect Aug. 3...

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel